SecBot SecBot

MGNX

MACROGENICS INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001125345 Biotech & Drug Discovery
$2.17 −0.03 (−1.36%)
Nov 16 4:00 PM ET · prev $2.20
Market cap
$146.4M
Micro cap
Median target
$8.50
+292% · range $4.00–11.00
1 year
+43.7%
from $1.51 · Nov 17
30 days
−34.8%
from $3.33
52-week range
$1.33–4.86
−55% from high · low Dec 8
Avg volume 20D
1.10M
Oct 23 spike 4.01M
Short interest
4.95M
≈7.8% of shares · −2.2%
Days to cover
3.9
at average volume
Insider net
−$129.1K
0 buyers · 1 seller · since Feb 12
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read MIXED 10 reports · 90 days
Balance 1 bearish · 2 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 6/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $129.1K.

  • InstitutionsMIXED

    Q3 2026: 14 added (0 new), 15 trimmed or exited.

  • Short sellersSTEADY

    Short interest −2.2% to 4.95M shares. 3.9 days to cover, ≈7.8% of shares.

  • TrendDOWNTREND

    34% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 26.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD6,149,936$23.7M
WASATCH ADVISORS LPTRIM1,260,901$4.9M
STATE STREET CORPADD1,167,355$4.5M
FMR LLCDOUBLED419,014$1.6M
Nuveen, LLCADD194,534$750.9K
STRS OHIOADD178,400$688.6K
Russell Investments Group, Ltd.DOUBLED144,296$557.0K
MORGAN STANLEYADD118,713$458.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026
12-month targets · 4 analysts

Price is below the lowest target. Median implies +292%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Aug 17, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy
Reddit
Recent posts
All social signals and their track records

Insider ledger

Form 4
$0
bought · 0 insiders
$129.1K
sold · 1 insider
DateInsiderTypeValue
Oct 30, 2026
Kuriakose Emil
Director
Oct 30, 2026
AWARD7,500 sh
Oct 30, 2026
Kuriakose Emil
Director
Oct 30, 2026
AWARD44,000 sh
Oct 30, 2026
VASCONCELLES MICHAEL
Director
Oct 30, 2026
AWARD44,000 sh
Oct 30, 2026
VASCONCELLES MICHAEL
Director
Oct 30, 2026
AWARD7,500 sh
Oct 6, 2026
Bonvini Ezio
Sr VP, Research & CSO
Oct 6, 2026
EXERCISE$20.8K
Aug 19, 2026
Peters Jeffrey Stuart
Senior VP, GC, and Secretary
Aug 19, 2026
SELL$129.1K
Aug 17, 2026
Bonvini Ezio
Sr VP, Research & CSO
Aug 17, 2026
EXERCISE$104.0K
May 19, 2026
Koenig Scott
Director
May 19, 2026
AWARD22,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
4,949,641
shares short
-2.2%
vs prior settlement
3.9
days to cover
≈7.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
MacroGenics posted a corporate presentation on its website with updated clinical data for its B7-H3 ADC MGC026…
8-K · Impact 4/10
Nov 12, 2026 SEC
MacroGenics reported Q3 2026 revenue of $18.7M, well below the $39.2M consensus, and a GAAP net loss of $20.1M (EPS…
PRESS-RELEASE · Impact 5/10
Nov 12, 2026 Earnings
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
ROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage
Oct 30, 2026 Insider
Kuriakose Emil was granted 7,500 shares
Director
Oct 30, 2026 Insider
Kuriakose Emil was granted 44,000 shares
Director
Oct 30, 2026 Insider
VASCONCELLES MICHAEL was granted 44,000 shares
Director
Oct 26, 2026 Press
MacroGenics announced positive interim Phase 2 LINNET data for lorigerlimab in clear cell gynecologic cancer (CCGC)…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent

SecBot reports

16 filings · 5 press releases · 5 bullish · 1 bearish · 1 mixed · 9 neutral
All MGNX filing & press-release reports (21)